CJC-1295 + Ipamorelin Consent Template
$599
CJC-1295 and Ipamorelin is a synergistic peptide combination therapy designed to stimulate the body’s natural production and release of growth hormone. CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue — together, they work through complementary pathways to promote a more sustained and controlled release of growth hormone compared to either peptide alone.
This combination is being explored for its potential to support muscle growth, fat metabolism, recovery, sleep quality, and overall vitality — with particular interest in its anti-aging and body composition benefits.
Before beginning treatment, all patients complete a comprehensive informed consent process covering how CJC-1295 and Ipamorelin work individually and in combination, potential benefits, known side effects, contraindications, and patient responsibilities. As this combination therapy is not FDA-approved, all use is considered investigational and is conducted under qualified medical supervision.
